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Abstract
Background: Glucosamine (GlcN) used by patients with osteoarthritis was demonstrated to
reduce pain, but the working mechanism is still not clear. Viscosupplementation with hyaluronic
acid (HA) is also described to reduce pain in osteoarthritis. The synthesis of HA requires GlcN as
one of its main building blocks. We therefore hypothesized that addition of GlcN might increase
HA production by synovium tissue.
Methods: Human osteoarthritic synovium explants were obtained at total knee surgery and pre-
cultured for 1 day. The experimental conditions consisted of a 2 days continuation of the culture
with addition of N-Acetyl-glucosamine (GlcN-Ac; 5 mM), glucosamine-hydrochloride (GlcN-HCl;
0.5 and 5 mM), glucose (Gluc; 0.5 and 5 mM). Hereafter HA production was measured in culture
medium supernatant using an enzyme-linked binding protein assay. Real time RT-PCR was
performed for hyaluronic acid synthase (HAS) 1, 2 and 3 on RNA isolated from the explants.
Results: 0.5 mM and 5 mM GlcN-HCl significantly increased HA production compared to control
(approximately 2 – 4-fold), whereas GlcN-Ac had no significant effect. Addition of 5 mM Gluc also
increased HA production (approximately 2-fold), but 0.5 mM Gluc did not. Gene expression of the
HA forming enzymes HAS 1, 2 and 3 was not altered by the addition of GlcN or Gluc.
Conclusion: Our data suggest that exogenous GlcN can increase HA production by synovium
tissue and is more effective at lower concentrations than Gluc. This might indicate that GlcN exerts
its potential analgesic properties through stimulation of synovial HA production.
Background
Glucosamine (GlcN) is popular among patients suffering
from osteoarthritis (OA). Although the efficacy of GlcN in
OA is still under debate, subgroup analysis in patients
with moderate-to-severe pain in a recent large NIH trial
indicated that glucosamine hydrochloride (GlcN-HCl)
might have a positive effect on pain [1]. Two clinical stud-
ies indicated that GlcN might have structure modifying
Published: 11 September 2008
BMC Musculoskeletal Disorders 2008, 9:120 doi:10.1186/1471-2474-9-120
Received: 22 January 2008
Accepted: 11 September 2008
This article is available from: http://www.biomedcentral.com/1471-2474/9/120
© 2008 Uitterlinden et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 7
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2008, 9:120 http://www.biomedcentral.com/1471-2474/9/120effects on cartilage in knee OA [2,3]. The claim of structure
modifying properties of GlcN is mostly based on the
effects on cartilage. However, cartilage is not innervated
and thus pain reduction after GlcN administration, as has
been reported in the previously mentioned NIH trial, can
therefore not be explained by the effect of GlcN on carti-
lage tissue. Considering pain reduction in OA, viscosup-
plementation with hyaluronic acid (HA) has been shown
to have beneficial effects on both pain and function in
patients with knee OA [4]. Since GlcN is an important
building block of HA and HA is found in high amounts in
articular joints, increasing HA production through the
administration of GlcN might be a way to explain the pain
relieving effect of GlcN. HA is synthesized by hyaluronic
acid synthases (HAS) which covalently link the mono-
meric building blocks glucuronic acid and N-Acetyl-glu-
cosamine (GlcN-Ac) in an alternating fashion. Hence, if
the HAS enzymes are at hand, availability of its building
blocks is another prerequisite for the synthesis of HA. But,
more availability of substrate does not necessarily have to
lead to more HA.
The aim our study was to evaluate whether GlcN deriva-
tives have an effect on HA production in a human syn-
ovium explant model. Specifically, we investigated if HA
production can be stimulated by adding GlcN and if GlcN
affects gene expression of the HAS enzymes.
Methods
Explant culture
Human synovium was obtained from patients suffering
from knee OA at time of total knee arthroplasty operation
(12 patients, age 48–70 male:female ratio 1:2, with
approval of the Ethical Committee number MEC 2004-
140). To remove any remaining synovial fluid or blood,
raw material was rinsed three times in physiological
saline. From this raw material explants of approximately
3 mm2 each were created with a scalpel and pooled in a
Petri dish. Per condition, explants were randomly taken
from the Petri dish and cultured in a 6-well plate with 3
ml culture medium per well. During the whole experi-
ment this culture medium consisted of low glucose (1000
mg/l l = 5.55 mM) D-MEM (Gibco, Grand Island, NY),
supplemented with 10% fetal calf serum (containing 0.5
mM glucose), 50 μg/ml gentamicin, 1.5 μg/ml fungizone.
The total amount of explants per patient differed. There-
fore, care was taken to use an equal number of explants
per culture condition within one patient. In the final anal-
ysis, results were corrected for total sample weight.
After a 24 hour pre-culture period (day 1), the culture
medium was refreshed and the actual experiment was
started by supplementing the culture medium with differ-
ent derivatives for 48 hours (day 2–3).
In the first series of experiments (N = 6 patients) the effect
of different GlcN derivatives on HA production was stud-
ied. Therefore, the culture medium was supplemented
with GlcN-HCl (Sigma, St. Louis, MO) or GlcN-Ac
(Sigma, St. Louis, MO) at 5 mM.
In the second series of experiments (N = 6 patients) we
investigated the effect of different GlcN concentrations on
HA production. We also investigated the effect of glucose
(Gluc) concentrations similar to that of GlcN on HA pro-
duction, since in vivo GlcN is being formed from Gluc.
Finally, in the second series of experiments the effect of
GlcN and Gluc on HAS gene expression was studied. In
this second series of experiments the culture medium was
supplemented with GlcN-HCl or Gluc (Sigma, St. Louis,
MO) at 0.5 mM and 5 mM, respectively. In all experi-
ments the culture medium without GlcN or extra Gluc
supplementation was used as a control.
For all experiments, at day 3 medium supernatant was
stored at -20°C for analysis, explants were harvested and
the wet weight per sample was determined. The explants
from experiment 2 were snap frozen in liquid nitrogen for
RNA isolation.
Analysis
HA synthesis was measured in culture medium using an
enzyme-linked binding protein assay (Hyaluronic Acid
test Kit, Corgenix Inc., Westminster, CO) in a 96 wells
plate. The wells were coated with HA binding protein
from bovine cartilage to capture HA and an enzyme-con-
jugated version of HA binding protein to detect and meas-
ure HA in the sample using a spectrophotometer at 450
nm (650 nm reference). HA from rooster comb was used
as standard. The resulting amount of HA in the culture
medium was corrected for sample weight. For display pur-
poses, these values were expressed relative to the control
condition on day 3.
The wet weight per sample of the snap frozen explants
from experiment 2 was determined and the frozen syn-
ovium was then processed using the Mikro-Dismembra-
tor S® (B. Braun Biotech International GmbH, Melsungen,
Germany). RNA was extracted using RNA-Bee™ (TEL-
TEST, Inc; Friendswood, TX, USA) according to manufac-
turer's guidelines and subsequently precipitated with 2-
propanol. RNA was further purified using RNeasy Micro
Kit (Qiagen, Venlo, The Netherlands) with on-column
DNA-digestion. Total RNA was quantified accurately
using a NanoDrop™ 1000 spectrophotometer (Nanodrop
technologies, Wilmington, DE) according to manufac-
turer's instructions and 500 ng total RNA of each sample
was reverse transcribed into cDNA using RevertAid™ First
Strand cDNA Synthesis Kit (MBI Fermentas, Germany).
TaqMan® assays were performed on an ABI Prism 7000 forPage 2 of 7
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systems, Foster City, CA, order numbers HAS1:
Hs00758053_m1, HAS2: Hs00193435_m1, HAS3:
Hs00193436_m1). Tissue processing and gene expression
analysis were performed using the same protocol we
described earlier in our study on human osteoarthritic car-
tilage explants [5].
For each patient the Ct-values of each control and experi-
mental condition were normalized to glyceraldehyde 3-
phosphate dehydrogenase. Hereafter each experimental
condition was expressed relative to the corresponding
control condition of the same patient, according to the 2-
ΔΔCt method described by Livak et al. [6,7]. The resulting
number of this calculation indicated whether there was an
up or down-regulation of gene expression of an experi-
mental condition compared to its paired untreated con-
trol. Thereafter, for each subset of experimental
conditions the median of these numbers was calculated.
For graphical display purposes only the 2-ΔΔCt values were
expressed as a 10LOG. For statistical analysis a Friedman
test with post-hoc Wilcoxon signed ranks test was per-
formed on the amount of HA in the culture medium cor-
rected for sample weight (HA production) and on the
normalized Ct values (gene expression), using SPSS
11.5.0 (SPSS Inc., Chicago, IL). A p-value ≤ 0.05 was con-
sidered to indicate statistically significant differences.
Results
In the first set of experiments, the amount of HA in the
medium was increased significantly 3.66 fold by the addi-
tion of 5 mM GlcN-HCl when compared to the control
condition (Fig. 1). The increase after addition of 5 mM
GlcN-Ac was not statistically significant.
In the second set of experiments, in which samples from
6 other patients were used, HA in the culture medium was
significantly increased by 0.5 mM GlcN-HCl (204%) and
5 mM GlcN-HCl (207%) and by addition of 5 mM Gluc
(178%), but not by 0.5 mM Gluc (Fig 2).
Furthermore, all three HAS isoforms were expressed in the
synovium explants. No statistically significant difference
in gene expression was found for the experimental condi-
tions, compared to the control condition (Fig. 3).
Discussion
Addition of 0.5 mM or 5 mM GlcN-HCl to human oste-
oarthritic synovium explants in vitro led to more HA in the
medium when compared to the control condition. 5 mM
GlcN-Ac did not have a significant effect on medium HA
concentration.
To this date several in vitro studies have been published
on the possible working mechanisms of GlcN in OA.
Interference with catabolic activities and stimulation of
anabolic activities on chondrocytes have both been
reported for GlcN in vitro. Studies investigating the influ-
HA after addition of 5 mM GlcN-Ac or GlcN-HCl to human synovium explantsFigure 1
HA after addition of 5 mM GlcN-Ac or GlcN-HCl to human synovium explants. Amount of hyaluronic acid secreted 
into culture medium after 48 hours treatment of human osteoarthritic synovium explants with 5 mM GlcN-Ac (N = 6) or 5 
mM GlcN-HCl (N = 6) for 2 days. Values are expressed relative to the non-treated (NT) control condition which is set at 
100% (N = 6, first bar). * indicates a statistically significant difference (p = 0.028).
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down of cartilage, with a culture system using interleukin-
1, lipopolysaccharide or retinoic acid to induce catabolic
effects, reported less matrix metalloproteinase activity and
aggrecanase activity by addition of GlcN [8-13]. Studies
considering the possible anabolic effects of GlcN pro-
posed that addition of GlcN led to more glycosaminogly-
can production by chondrocytes, since GlcN is the basic
HA after addition of 0.5 and 5 mM GlcN-HCl or Gluc to human synovium explantsFigure 2
HA after addition of 0.5 and 5 mM GlcN-HCl or Gluc to human synovium explants. Amount of hyaluronic acid 
secreted into culture medium after 48 hours treatment of human osteoarthritic synovium explants with 0.5 mM GlcN-HCl (N 
= 6), 5 mM GlcN-HCl (N = 6), 0.5 mM Gluc (N = 5) or 5 mM Gluc (N = 6) for 2 days. Values are expressed relative to the 
non-treated (NT) control condition which is set at 100% (N = 6, first bar). * indicates a statistically significant difference (p = 
0.028).
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HAS gene expression after addition of GlcN-HCl or Gluc to human synovium explantsFigur  3
HAS gene expression after addition of GlcN-HCl or Gluc to human synovium explants. Change in HAS gene 
expression in human osteoarthritic synovium explants after culture with glucosamine or glucose. Synovium explants were pre-
cultured for 1 day, followed by 2 days of treatment with 0.5 mM GlcN-HCl (N = 6), 5 mM GlcN-HCl (N = 5), 0.5 mM Gluc (N 
= 5) and 5 mM Gluc (N = 6). The n-fold change for HAS1 (panel A), HAS2 (panel B) and HAS3 (panel C), normalized to glycer-
aldehyde 3-phosphate dehydrogenase and relative to the untreated control (indicated by the dotted line) is displayed on the 
vertical axis. Negative values indicate down-regulation and positive values indicate up-regulation of gene expression. No statis-
tically significant differences were found.
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BMC Musculoskeletal Disorders 2008, 9:120 http://www.biomedcentral.com/1471-2474/9/120building block of glycosaminoglycan molecules [9,14-
17]. These studies were performed with chondrocytes of
different species.
Being a rate-limiting precursor in HA synthesis, GlcN was
suggested earlier to exert its effects in OA influencing syn-
ovial HA synthesis [18,19]. However, direct scientific
proof for this was still absent. To our knowledge this is the
first study that investigated the effect of GlcN on human
OA synovium explants.
In experiment 1 with synovium samples from 6 patients
addition of 5 mM GlcN-Ac did not lead to a significant
increase in medium HA. Therefore in experiment 2, in
which samples from 6 other patients were used, only the
effects of the derivative GlcN-HCl were tested at different
concentrations and relative to Gluc treatment. In one of
our earlier studies using bovine chondrocytes we also
found that GlcN-Ac had a different effect on gly-
cosaminoglycan production when compared to GlcN-HCl
[20]. We speculate that this difference might be due to in
the interference of the covalently bound acetyl group as
opposed to the ionically bound, and therefore easy to dis-
solve, hydrochloride salt.
HA is found in almost all tissues, and plays key roles in
many cellular processes such as migration, proliferation,
differentiation and regulation of matrix organization [21].
HA is one of the main components of synovial fluid in
articular joints and plays a major role in joint lubrication
and in maintaining joint homeostasis [22]. In inflamma-
tory joints, lower concentration of HA as well as lower
molecular weight of HA have been described [23]. Size
and concentration of HA determine the viscoelastic prop-
erties as well as regulate the inflammatory and tissue
repair responses [24,25]. HA was also shown to be able to
have anti-inflammatory effects on OA specific cytokines
by down-regulation of tumor necrosis factor alpha, inter-
leukin-8 [26]. HA, a polymer of alternating glucuronic
acid and GlcN-Ac units is being synthesized at the inside
of the cell at the plasma membrane, and then released
into the extracellular matrix [27]. In accordance with
Recklies et al. our results demonstrate that all 3 isoforms
of HAS, the enzyme responsible for the synthesis of HA,
are expressed by synovium [28]. Recklies et al. observed
that the HAS1 message levels were always more abundant
than that for HAS2 in synovial cells, and that the HAS3
message levels were always least abundant. In experiment
2, our mean Ct values showed a similar trend (data not
shown). Addition of GlcN-HCl or Gluc did not alter HAS
gene expression significantly. Thus, direct up-regulation
of HAS gene expression does not seem to be the explana-
tion for the increased amount of HA in the medium in our
experiments. Since HAS gene expression was not affected
by GlcN, apart from simply providing more building
blocks, GlcN could also have played a role in HA synthesis
by influencing HAS enzymatic activity or protein levels. In
the current study design this was not investigated, and
therefore this possibility can not be commented on.
The increased amount of HA in the culture medium might
be explained by the fact that addition of GlcN-HCl simply
led to more building blocks that are required for the syn-
thesis of HA. Our results showed that a concentration of
exogenous GlcN ten times lower than the medium Gluc
concentration already led to significantly more HA pro-
duction. This indicated a more effective and perhaps spe-
cific effect of exogenous GlcN as opposed to endogenous
GlcN that is formed intracellular using medium Gluc as
substrate.
The major limitation of our study was the use of relatively
high concentrations of GlcN when compared to the in vivo
situation. A recent report by Persiani et al. [29] showed
that synovial GlcN concentration varied between 3 and 18
μM after oral administration at the therapeutic dose of
1500 mg once-a-day. In many earlier reports, including
our own, much higher concentration have been used for
in-vitro studies [5,10-13,20,30-34]. In chondrocytes it has
been demonstrated that exogenous GlcN was incorpo-
rated in newly formed chondroitin sulphate when added
at an equimolar concentration with Gluc in the culture
medium. When Gluc concentration increased, chondro-
cytes preferably incorporated GlcN that was endog-
enously formed from Gluc [35,36]. These results
suggested that in chondrocytes the GlcN to Gluc ratio
played an important role in the utilization and therefore
effectiveness of exogenously provided GlcN. Since we did
not know whether this was also the case for synovium, we
decided to use an equimolar and ten times lower GlcN
concentration compared to medium Gluc concentration.
When trying to translate our in vitro results to clinical
applicability of GlcN, the intra-articular GlcN concentra-
tion that can be reached after administration of GlcN to
the patient is reason of concern and thus weakens the
direct clinical relevance of our work. Since the first studies
were performed on the effect of GlcN there has been
debate on this topic. When GlcN-HCl was administered to
horses in a single dose, intravenously as well as orally, in
a dosage per kg bodyweight at clinically relevant levels,
GlcN was still detectable in synovial fluids 6 hours after it
was nearly completely cleared from the serum [37].
Although GlcN can thus be retained in joint fluid, it must
still be questioned whether the levels of 0.5 mM or 5 mM
GlcN will ever be reached in the joint. Therefore, future
studies should look into the effect of lower GlcN concen-
trations on synovial HA production. Our result should be
interpreted as a proof of concept on the possible working
mechanism of GlcN in OA.Page 5 of 7
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2008, 9:120 http://www.biomedcentral.com/1471-2474/9/120Conclusion
In conclusion, the results of our experiments suggest that
GlcN-HCl increases the production of HA in synovium.
Our results were obtained with GlcN concentrations
much higher than thus far have been reported in human
synovial fluid after oral ingestion of a therapeutic dose
[29]. Further studies are needed to investigate the effect of
GlcN concentrations more likely to be reached in the
human joint, before any decision can be made upon the
clinical relevancy of GlcN ingestion on synovial HA pro-
duction.
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